サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：クラッベ病治療の世界市場（2022年～2029年）
市場調査レポート
商品コード
1082813

クラッベ病治療の世界市場（2022年～2029年）

Global Krabbe Disease Treatment Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
クラッベ病治療の世界市場（2022年～2029年）
出版日: 2022年06月03日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のクラッベ病治療について調査分析し、市場の概要とともに、市場動向、市場促進・抑制要因、COVID-19の影響、業界分析、セグメント別・地域別の市場分析、競合情勢、企業プロファイルなどの情報を提供しています。

目次

第1章 世界のクラッベ病治療市場：範囲と調査手法

  • 調査手法
  • 調査の目的と調査範囲

第2章 世界のクラッベ病治療市場：市場の定義と概要

第3章 世界のクラッベ病治療市場：エグゼクティブサマリー

  • 疾病タイプ別の市場内訳
  • 診断別市場内訳
  • 治療別市場内訳
  • エンドユーザー別市場内訳
  • 流通チャネル別の市場内訳
  • 地域別の市場内訳

第4章 世界のクラッベ病治療市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因：
    • 市場機会
    • 影響分析

第5章 世界のクラッベ病治療市場：業界分析

  • サプライチェーン分析
  • 価格分析
  • アンメットニーズ

第6章 世界のクラッベ病治療市場：COVID-19分析

  • 市場へのCOVID-19の影響分析
    • COVID-19前の市場シナリオ
    • 現在のCOVID-19の市場シナリオ
    • COVID-19後または将来のシナリオ
  • COVID-19における価格変動
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • 結論

第7章 世界のクラッベ病治療市場：疾病タイプ別

  • イントロダクション
    • 市場規模分析・前年比成長分析（％）：疾病タイプ別
    • 市場魅力指数：疾病タイプ別
  • 乳児性
    • イントロダクション
    • 市場規模分析・前年比成長分析（％）：2020年～2029年、および2021年～2029年（百万米ドル）
  • 遅発性

第8章 世界のクラッベ病治療市場：診断別

  • イントロダクション
    • 市場規模分析・前年比成長分析（％）：診断別
    • 市場魅力指数：診断別
  • 臨床検査
    • 血液検査
    • その他
    • イントロダクション
    • 市場規模分析・前年比成長分析（％）：2020年～2029年、および2021年～2029年（百万米ドル）
  • 画像検査
    • 磁気共鳴画像法（MRI）
    • コンピューター断層撮影（CT）
    • その他
  • 遺伝子検査
  • 新生児スクリーニング
  • その他

第9章 世界のクラッベ病治療市場：治療別

  • イントロダクション
    • 市場規模分析・前年比成長分析（％）：治療別
    • 市場魅力指数：治療別
  • 抗けいれん薬
    • アセタゾラミド
    • カルバマゼピン
    • テグレトール
    • クロバザム
    • ガバペンチン
    • その他
    • イントロダクション
    • 市場規模分析・前年比成長分析（％）：2020年～2029年、および2021年～2029年（百万米ドル）
  • 筋弛緩薬
    • チザニジン
    • カリソプロドール
    • クロルゾキサゾン
    • メタキサロン
    • その他
  • 骨髄移植
  • 幹細胞移植
  • その他

第10章 世界のクラッベ病治療市場：エンドユーザー別

  • イントロダクション
    • 市場規模分析・前年比成長分析（％）：エンドユーザー別
    • 市場魅力指数：エンドユーザー別
  • 病院
    • イントロダクション
    • 市場規模分析・前年比成長分析（％）：2020年～2029年、および2021年～2029年（百万米ドル）
  • 診断センター
  • クリニック
  • その他

第11章 世界のクラッベ病治療市場：流通チャンネル別

  • イントロダクション
    • 市場規模分析・前年比成長分析（％）：流通チャンネル別
    • 市場魅力指数：流通チャンネル別
  • 病院薬局
    • イントロダクション
    • 市場規模分析・前年比成長分析（％）：2020年～2029年、および2021年～2029年（百万米ドル）
  • 小売薬局
  • オンライン薬局
  • その他

第12章 世界のクラッベ病治療市場：地域別

  • イントロダクション
    • 地域別の市場規模分析・前年比成長分析（％）：2020年～2029年、および2021年～2029年（百万米ドル）
    • 地域別の市場魅力指数
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析（％）：疾患タイプ別
    • 市場規模分析・前年比成長分析（％）：診断別
    • 市場規模分析・前年比成長分析（％）：治療別
    • 市場規模分析・前年比成長分析（％）：エンドユーザー別
    • 市場規模分析・前年比成長分析（％）：流通チャネル別
    • 市場規模分析・前年比成長分析（％）：国別
  • 欧州
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析（％）：疾患タイプ別
    • 市場規模分析・前年比成長分析（％）：診断別
    • 市場規模分析・前年比成長分析（％）：治療別
    • 市場規模分析・前年比成長分析（％）：エンドユーザー別
    • 市場規模分析・前年比成長分析（％）：流通チャネル別
    • 市場規模分析・前年比成長分析（％）：国別
  • 南米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析（％）：疾患タイプ別
    • 市場規模分析・前年比成長分析（％）：診断別
    • 市場規模分析・前年比成長分析（％）：治療別
    • 市場規模分析・前年比成長分析（％）：エンドユーザー別
    • 市場規模分析・前年比成長分析（％）：流通チャネル別
    • 市場規模分析・前年比成長分析（％）：国別
  • アジア太平洋
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析（％）：疾患タイプ別
    • 市場規模分析・前年比成長分析（％）：診断別
    • 市場規模分析・前年比成長分析（％）：治療別
    • 市場規模分析・前年比成長分析（％）：エンドユーザー別
    • 市場規模分析・前年比成長分析（％）：流通チャネル別
    • 市場規模分析・前年比成長分析（％）：国別
  • 中東とアフリカ
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析（％）：疾患タイプ別
    • 市場規模分析・前年比成長分析（％）：診断別
    • 市場規模分析・前年比成長分析（％）：治療別
    • 市場規模分析・前年比成長分析（％）：エンドユーザー別
    • 市場規模分析・前年比成長分析（％）：流通チャネル別

第13章 競合情勢

  • 主な発展と戦略
  • 企業シェア分析
  • 製品のベンチマーク
  • 注目すべき主要企業のリスト

第14章 企業プロファイル

  • Lannett
    • 企業概要
    • 製品ポートフォリオ・説明
    • 主要ハイライト
    • 財務概要
  • Novartis
  • Lundbeck
  • Lupin Pharmaceuticals, Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Meda Pharmaceuticals Inc
  • Mayne Pharma Group Limited
  • Pfizer Inc.
  • Schwarz Pharma, Inc
  • Acorda Therapeutics Inc.

第15章 世界のクラッベ病治療市場：DataM

目次
Product Code: DMPH5230

Market Overview

The global krabbe disease treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Krabbe disease is a life-threatening neurological disorder commonly known as globoid cell leukodystrophy. It is one of a series of conditions known as leukodystrophies, caused by the breakdown of myelin in the nervous system (demyelination). Myelin is the protective layer that surrounds nerve cells and ensures that nerve signals are transmitted quickly. Krabbe illness is also characterized by aberrant brain cells known as globoid cells, huge cells with more than one nucleus. Krabbe disease is identified in children as young as six years old, and there is presently no cure; nevertheless, the condition is controlled by supportive care.

Market Dynamics

Advancement in the therapies for the treatment of Krabbe Disease is expected to drive market growth.

Other experimental medicines have demonstrated varying degrees of effectiveness in preclinical testing, with some of the best results from combining medications. For instance, HSCT has been used with SRT and gene therapy. The combinations consistently yield better outcomes than the matched individual therapies. Other approaches such as ERT, chaperone therapy, and anti-inflammatory therapy also have the potential to contribute as part of a combination or standalone therapies. Moreover, various clinical studies have been carried out. For instance, D-Cycloserine is an FDA-approved medicine for tuberculosis tested in numerous clinical studies for various diseases. Preliminary data suggest that it can slow disease progression in twitcher mice; consequently, D-cycloserine should be studied further to see if it can help individuals with Krabbe disease. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

The finite patient pool for clinical trials, lack of awareness of the disease and side effects of the drugs are factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The risk of severe forms of COVID-19 may be high in the rare metabolic community, where all patients, including children, experience multiorgan impairments due to their chronic condition. MetabERN, the European Reference Network for Hereditary Metabolic Diseases, conducted two surveys: one for patients' organizations (PO) and the other for healthcare providers (HCPs). COVID-19 incidence was lower in the community of uncommon metabolic patients (72.9 per 100,000 vs. 117 per 100,000) than in the general European population. On the other hand, patients were subjected to significant disruptions in their care, with most appointments and treatments being canceled, curtailed, or postponed. Almost all HCPs (90 percent) used telemedicine to replace face-to-face visits, about half of patients undergoing treatment changes switched from hospital to home therapy, and a quarter of patients had difficulty getting their medications.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Stem cell transplantation segment is expected to hold the largest market share in krabbe disease treatment market

The stem cell transplantation segment is expected to dominate in 2021. The segment benefits because if treatment begins before the development of symptoms, that is, when a diagnosis is made via a newborn screening test, this therapy may improve outcomes in newborns. According to current evidence, stem cell transplantation is most beneficial when initiated before a newborn reaches the age of two weeks. Moreover, Pre-symptomatic children who have stem cell transplantation had a slower disease progression and a better quality - and duration - of life than children who do not receive stem cell transplantation before symptoms arise, according to studies. Furthermore, This medication may also benefit older children and adults with modest Krabbe disease symptoms. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global krabbe disease treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of Krabbe Disease, rising geriatric population, Rapid adoption of cutting-edge technologies and novel medications for the treatment of Krabbe illness, well-established infrastructure and increase in clinical development of the treatment for the Krabbe disease, and rise in investment in research & development are some of the factors the market is expected to boost in the forecast period. For instance, the Krabbe disease affects about 1 in 100,000 people in the United States. It is also known as globoid cell leukodystrophy. Males are affected as often as females.

Also, more than two-fifths of all known cases of Krabbe disease is caused by a missense mutation in the GLC enzyme. Therapeutic approaches for other lysosomal storage diseases are ineffective in treating Krabbe disease due to the lack of accumulated primary substrate within the lysosome and the predominant CNS sickness. The molecules are being researched because they have the potential to pass the blood-brain barrier more efficiently than enzymes due to certain properties such as low molecular weight, low toxicity, and high bioavailability. Allosteric chaperones, directed away from the enzyme's active site, have also been found. Pharmacological chaperone therapy, which is expected to be effective, can be used to treat Krabbe disease. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the krabbe disease treatment market are Lannett, Novartis, Lundbeck, Lupin Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Meda Pharmaceuticals Inc , Mayne Pharma Group Limited, Pfizer Inc., Schwarz Pharma, Inc, Acorda Therapeutics Inc.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

­Product Portfolio:

SKELAXIN(metaxalone): Metaxalone is a muscle relaxant. It works by blocking nerve impulses (or pain sensations) in the brain. It is used with rest and physical therapy to treat skeletal muscle conditions such as pain or injury.

Why Purchase the Report?

Visualize the composition of the krabbe disease treatment market segmentation by disease type, diagnosis, treatment, end user, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in krabbe disease treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of krabbe disease treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global krabbe disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Diagnosis
  • 3.3. Market Snippet by Treatment
  • 3.4. Market Snippet by End user
  • 3.5. Market Snippet by Distribution channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancement in the therapies for the treatment of Krabbe Disease is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness of the disease and side effects of the drugs are factors the market is expected to hamper in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type Segment
  • 7.2. Infantile*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Late-onset

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 8.2. Laboratory tests*
    • 8.2.1. Blood Test
    • 8.2.2. Others
    • 8.2.3. Introduction
    • 8.2.4. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Imaging tests
    • 8.3.1. Magnetic resonance imaging (MRI)
    • 8.3.2. Computerized tomography (CT)
    • 8.3.3. Others
  • 8.4. Genetic testing
  • 8.5. Newborn screening
  • 8.6. Others

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment Segment
  • 9.2. Anticonvulsant Agents*
    • 9.2.1. Acetazolamide
    • 9.2.2. Carbamazepine
    • 9.2.3. Tegretol
    • 9.2.4. Clobazam
    • 9.2.5. Gabapentin
    • 9.2.6. Others
    • 9.2.7. Introduction
    • 9.2.8. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Muscle Relaxer Drugs
    • 9.3.1. Tizanidine
    • 9.3.2. Carisoprodol
    • 9.3.3. Chlorzoxazone
    • 9.3.4. Metaxalone
    • 9.3.5. Others
  • 9.4. Bone Marrow Transplantation
  • 9.5. Stem cell transplantation
  • 9.6. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Centers
  • 10.4. Clinics
  • 10.5. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. Lannett*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Novartis
  • 14.3. Lundbeck
  • 14.4. Lupin Pharmaceuticals, Inc.
  • 14.5. Teva Pharmaceuticals USA, Inc.
  • 14.6. Meda Pharmaceuticals Inc
  • 14.7. Mayne Pharma Group Limited
  • 14.8. Pfizer Inc.
  • 14.9. Schwarz Pharma, Inc
  • 14.10. Acorda Therapeutics Inc.

LIST NOT EXHAUSTIVE

15. Global Krabbe Disease Treatment Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us